Get the Stockscreener App
67.40
1.51%
-1.03
Dexcom Inc stock is traded at $67.40, with a volume of 7.76M.
It is down -1.51% in the last 24 hours and up +1.61% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
See More
Previous Close:
$68.43
Open:
$68.61
24h Volume:
7.76M
Relative Volume:
1.36
Market Cap:
$26.29B
Revenue:
$4.30B
Net Income/Loss:
$571.50M
P/E Ratio:
47.18
EPS:
1.4285
Net Cash Flow:
$570.80M
1W Performance:
+1.29%
1M Performance:
+1.61%
6M Performance:
-20.58%
1Y Performance:
-15.84%
1-Day Range:
$65.60
$68.89
1-Week Range:
$65.19
$70.92
52-Week Range:
$54.11
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
67.40 | 26.69B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
125.92 | 219.41B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
97.64 | 145.84B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.54 | 140.43B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
97.53 | 126.52B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 49.08B | 5.88B | 1.34B | 799.60M | 2.3489 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
DexCom (DXCM) Price Target Raised by Bernstein | DXCM Stock News - GuruFocus
Bernstein Adjusts Price Target on DexCom to $86 From $84, Maintains Outperform Rating - MarketScreener
Why Dexcom (DXCM) Is Up 5.6% After Naming New CEO And Advancing AI Diabetes Platform - Sahm
How DexCom Inc. stock compares to growth peersMarket Movement Recap & Low Risk High Reward Ideas - ulpravda.ru
Will DexCom Inc. stock benefit from sector rotationTrade Entry Summary & Reliable Breakout Stock Forecasts - ulpravda.ru
DexCom (DXCM) Stock Falls as Analysts Adjust Price Targets | Jan 2026News and Statistics - IndexBox
How DexCom Inc. stock performs in weak economyTake Profit & Safe Capital Growth Stock Tips - ulpravda.ru
Dexcom Finishes Off Class Claims Over Sales Growth Statements - Bloomberg Law News
DexCom (DXCM) Stock Trades Down, Here Is Why - Finviz
Why DexCom Inc. stock is rated strong buyTreasury Yields & Reliable Volume Spike Trade Alerts - ulpravda.ru
Published on: 2026-01-08 22:18:15 - ulpravda.ru
Is DexCom Inc. stock a good choice for value investorsVolume Spike & Short-Term Trading Opportunity Alerts - ulpravda.ru
Dexcom CEO Jake Leach Takes the Helm, Presents Future at CES - Medical Product Outsourcing
Dexcom enters next era of continued innovation with Jake Leach as chief executive officer - MarketScreener
Dexcom CEO Jake Leach begins tenure with focus on metabolic health By Investing.com - Investing.com South Africa
Dexcom CEO Jake Leach begins tenure with focus on metabolic health - Investing.com UK
Dexcom Enters Next Era of Continued Innovation With Jake Leach as President and Chief Executive Officer - DexCom Investor Relations
Is DexCom, Inc.'s (NASDAQ:DXCM) Recent Stock Performance Tethered To Its Strong Fundamentals? - 富途牛牛
DexCom Inc. Stock Outperforms Competitors On Strong Trading Day - 富途牛牛
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
UBS (AMUB) DexCom-linked trigger autocallable notes detail coupons and downside risk - Stock Titan
Dexcom Inc. Bets Big on Continuous Glucose Monitoring — and It’s Winning - AD HOC NEWS
Why pension funds invest in DexCom Inc. (DC4) stock2026 world cup usa national team qualification defensive leaders high defensive line knockout prediction preview - ulpravda.ru
DexCom Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
How DexCom Inc stock performs in weak economy2025 Performance Recap & AI Enhanced Trading Signals - moha.gov.vn
Dexcom names Jacob Leach as incoming chief executive - MSN
Assessing DexCom (DXCM) Valuation As Shares Lag Over The Past Year - Yahoo Finance
DexCom, Inc.'s (NASDAQ:DXCM) Stock Been Rising: Are Strong Financials Guiding The Market? - Yahoo Finance
Who Owns Dexcom? Top Shareholders and Recent Insider Trades - TIKR.com
DexCom, Inc. $DXCM Shares Sold by Ethic Inc. - Defense World
Dexcom Stock in Focus: Quiet Rally, Mixed Signals and a Data?Driven Bet on Connected Diabetes Care - AD HOC NEWS
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Mobile Health (mHealth) Technologies and Global Markets Report 2025-2030 Featuring Leading CompaniesApple, Samsung, AT&T, Medtronic, Abbott, Koninklijke Philips N.V., and DexcomResearchAndMarkets.com - The AI Journal
DexCom Inc Stock Price Live, Charts & News - The Economic Times
The Truth About DexCom Inc: Why Everyone Is Suddenly Watching DXCM - AD HOC NEWS
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium - TradingView — Track All Markets
DexCom Inc (NASDAQ:DXCM) Embodies the Growth at a Reasonable Price (GARP) Strategy - Chartmill
DexCom (NASDAQ:DXCM) & Avanos Medical (NYSE:AVNS) Head-To-Head Contrast - Defense World
Dexcom Stock Finds Its Range: What The Latest Drift, Data, And Deals Signal For 2026 - AD HOC NEWS
FDA says Dexcom issues correction for Dexcom G6 and G6 Pro software - marketscreener.com
E. Ohman J or Asset Management AB Raises Position in DexCom, Inc. $DXCM - MarketBeat
SWS Partners Purchases 19,073 Shares of DexCom, Inc. $DXCM - MarketBeat
Beacon Investment Advisory Services Inc. Trims Stock Position in DexCom, Inc. $DXCM - Defense World
Class Action Alert: Levi & Korsinsky Reminds DexCom (DXCM) Investors of December 26, 2025 Deadline - ACCESS Newswire
Recover Investment Losses: Class Action Initiated Against DexCom, Inc. (DXCM) - ACCESS Newswire
DexCom, Inc. Sued for Securities Law Violations – Investors - GlobeNewswire
DexCom, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before December 26, 2025 to Discuss Your RightsDXCM - Finviz
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, - GlobeNewswire
DEXCOM CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds DXCM Investors of the December 26th Deadline for Contacting the Firm - GlobeNewswire Inc.
DXCM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
DXCM DEADLINEFINAL REMINDER: Bronstein, Gewirtz & Grossman LLC Alerts DexCom, Inc. Investors to Participate in the Class Action Lawsuit - ACCESS Newswire
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.48%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):